Cyclacel Pharma (CYCC) Reports Q1 Loss Per Share of $0.19

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. CMG
7. TENB
8. BIIB
9. KLAC
10. CART

Go back to Cyclacel Pharma (CYCC) Reports Q1 Loss Per Share of $0.19

Cyclacel Pharmaceuticals Reports First Quarter 2015 Financial Results

May 12, 2015 4:05 PM EDT

-- Approximately 20% of prespecified events remaining in SEAMLESS before study unblinding -- -- Received FDA clearance for the first-in-human Phase 1 study of CYC065 CDK inhibitor -- -- Conference Call Scheduled May 12, 2015 at 4:30 p.m. Eastern Time --

BERKELEY HEIGHTS, N.J., May 12, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of... More